allogeneic TCR T-cell therapy (Kyoto University/National Cancer Center/Thyas/MaxCyte)

N/A

Report date: 2025/03/14 16:24:16

Base Information

Drug Nameallogeneic TCR T-cell therapy (Kyoto University/National Cancer Center/Thyas/MaxCyte)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionHuman leukocyte antigen modulators
TargetsHuman leukocyte antigen
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKyoto University
China Registration ClassN/A

Develop Information

Active CompaniesThyas Co LtdMaxcyte IncKyoto University +[4] 
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A